Alterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech event

Rhea-AI Filing Summary

Alterity Therapeutics, a clinical stage biotechnology company, announced that Chief Executive Officer David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026 on 28-29 July 2026, where he will host 1-on-1 meetings with investors in the United States.

The company develops disease modifying therapies for neurodegenerative diseases, focusing on Multiple System Atrophy and related Parkinsonian disorders. Alterity is preparing a Phase 3 pivotal trial in MSA for its lead asset ATH434, which has shown clinically meaningful efficacy and positive data in Phase 2 clinical studies.

Filing Explained

Alterity Therapeutics filed this July 21 Form 6-K as an interim report and states that it is being incorporated by reference into its existing Form S-8 and Form F-3 registration statements, making this a registration-document step rather than a reported issuance or sale of securities.

Key Figures

BTIG conference dates: 28-29 July 2026 Lead asset: ATH434 Planned trial stage: Phase 3 pivotal trial in MSA +1 more

4 metrics

BTIG conference dates 28-29 July 2026 Dates of the virtual BTIG Biotechnology Conference 2026 in which Alterity will participate

Lead asset ATH434 Lead drug candidate being developed for Multiple System Atrophy

Planned trial stage Phase 3 pivotal trial in MSA Alterity is preparing to initiate a Phase 3 pivotal trial for ATH434 in Multiple System Atrophy

Completed trial stage Phase 2 clinical trials in MSA ATH434 has shown clinically meaningful efficacy and positive data in Phase 2 MSA studies

Key Terms

Multiple System Atrophy (MSA), Phase 3 pivotal trial, randomized, double-blind, placebo-controlled Phase 2 clinical trial, open label Phase 2 clinical trial, +2 more

6 terms

Multiple System Atrophy (MSA) medical

"developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian"

A progressive neurological disorder in which brain cells that control movement, balance and automatic body functions (like blood pressure, bladder control and digestion) gradually fail, causing symptoms such as poor coordination, stiffness, fainting and urinary problems. Investors care because the condition drives demand for diagnostic tests, therapies and long-term care solutions; successful clinical trials, regulatory approvals or setbacks can materially affect the valuation and revenue prospects of companies developing treatments, devices or related services.

Phase 3 pivotal trial medical

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

randomized, double-blind, placebo-controlled Phase 2 clinical trial medical

"demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2"

open label Phase 2 clinical trial medical

"reported positive data in its open label Phase 2 clinical trial in participants"

disease modifying therapies medical

"The Company is focused on developing disease modifying therapies in Multiple System Atrophy"

Therapies that change the underlying course of a disease rather than only treating symptoms; they aim to slow, halt, or reverse the biological processes causing decline, like fixing a car’s engine instead of repeatedly patching the exhaust. Investors care because success can transform long-term patient need, pricing power, market size and regulatory value, so these treatments often carry higher rewards and higher clinical and approval risk than symptom-only drugs.

forward-looking statements regulatory

"This press release contains forward-looking statements within the meaning of section 27A"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/21/2026 - 06:04 AM Accepted by SEC EDGAR 07/21/2026 - 06:02 AM Learn about SEC filing dates

FAQ

What does Alterity Therapeutics (ATHE) report in this Form 6-K?

Alterity reports that CEO David Stamler, M.D. will participate in the virtual BTIG Biotechnology Conference 2026 on 28-29 July 2026, hosting 1-on-1 investor meetings and highlighting its neurodegenerative disease pipeline, including lead candidate ATH434 for Multiple System Atrophy.

What is Alterity Therapeutics (ATHE) focusing on in its drug pipeline?

Alterity focuses on disease modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. Its lead asset, ATH434, targets underlying neurological pathology and has reported clinically meaningful efficacy and positive data in Phase 2 MSA clinical trials.

What is the clinical status of ATH434 mentioned for Alterity (ATHE)?

ATH434 is Alterity’s lead asset for MSA. The company is preparing to initiate a Phase 3 pivotal trial after reporting clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive results from an open label Phase 2 trial in advanced MSA.

When and how will Alterity (ATHE) participate in the BTIG Biotechnology Conference 2026?

Alterity will take part in the conference virtually on 28-29 July 2026. CEO David Stamler, M.D., will host 1-on-1 meetings with U.S. investors, providing an opportunity to discuss the company’s MSA program, ATH434, and broader neurodegenerative disease pipeline.

What therapeutic areas does Alterity Therapeutics (ATHE) target?

Alterity targets neurodegenerative diseases, with a primary focus on Multiple System Atrophy (MSA) and related Parkinsonian disorders. It leverages a drug discovery platform that generates patentable compounds designed to address the underlying pathology of these neurological conditions.

Where is Alterity Therapeutics (ATHE) based and how can investors learn more?

Alterity is based in Melbourne, Australia, and San Francisco, California, USA. Investors can obtain further information and updates on its MSA trials, ATH434 development, and conference participation by visiting the company’s website at https://alteritytx.com.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Alterity to Participate in the BTIG Biotechnology Conference

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: July 21, 2026

2

Exhibit 99.1

Alterity Therapeutics to Participate in the

Virtual BTIG Biotechnology Conference 2026

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 21 July 2026:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in the BTIG Biotechnology Conference 2026 taking place virtually 28-29 July 2026.

At the conference, Dr. Stamler will host 1-on-1 meetings with investors in the United States.  

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 10.6 KB